Cite
HARVARD Citation
Sharman, J. et al. (2021). Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet. 8 (4), pp. e254-e266. [Online].